About: Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.03 (-2.71%)
ALGS NASDAQ Aligos Therapeutics Inc
Aligos Therapeutics Inc share price
Atividade de preço de ALGS
Último preço
$ 5,030
Variação (24h)
-0,14 USD (2,71%)
Volume
47.17K
Volume (média 4 sem.)
-
Abertura
$ 5,02
Variação do dia
$ 5,02 - $ 5,38
Fechamento anterior
$ 5,17
Último negócio
29 Oct, 8:07 pm GMT+0
Atrasado
29 Oct, 8:07 pm GMT+0
ALGS price performance
Atrasado
29 Oct, 8:07 pm GMT+0
quote.marketSignals